Literature DB >> 18279998

Environmental factors as disease accelerators during chronic hepatitis C.

Ariane Mallat1, Christophe Hezode, Sophie Lotersztajn.   

Abstract

Progression of chronic hepatitis is highly variable among individuals, as the result of several host, viral and environmental factors. The latter have been extensively investigated in order to ameliorate hepatitis C outcome, particularly in difficult-to-treat patients. Over the last decade, several studies have shown that a combination of HCV infection and high levels of alcohol abuse results in synergistic acceleration of liver fibrogenesis. In addition, recent data indicate that light alcohol intake may also exacerbate fibrosis progression. It has also been suggested that cigarette smoking may enhance activity grade in patients with chronic hepatitis C, thereby increasing progression of fibrosis. This assumption mostly relies on epidemiological evidences in the absence of pathogenic studies. Finally, cannabis use is increasingly emerging as a novel co-morbidity in patients with chronic hepatitis C. Indeed, regular cannabis smoking is an independent predictor of both fibrosis and steatosis severity in infected patients. In addition, experimental studies have shown that cannabinoid CB1 receptors enhance liver fibrogenesis and steatogenesis by distinct mechanisms, therefore strongly supporting epidemiological findings. Altogether, patients should be informed of the deleterious impact of alcohol, tobacco and cannabis use and should be offered appropriate support to achieve abstinence.

Entities:  

Mesh:

Year:  2008        PMID: 18279998     DOI: 10.1016/j.jhep.2008.01.004

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  17 in total

1.  Marijuana use in hepatitis C infection does not affect liver biopsy histology or treatment outcomes.

Authors:  Theresa Liu; Glenn T Howell; Lucy Turner; Kimberley Corace; Gary Garber; Curtis Cooper
Journal:  Can J Gastroenterol Hepatol       Date:  2014 Jul-Aug

2.  Molecular mechanisms involved in the interaction effects of alcohol and hepatitis C virus in liver cirrhosis.

Authors:  Valeria R Mas; Ryan Fassnacht; Kellie J Archer; Daniel Maluf
Journal:  Mol Med       Date:  2010-03-26       Impact factor: 6.354

Review 3.  Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.

Authors:  Amber Arain; Geert Robaeys
Journal:  World J Gastroenterol       Date:  2014-09-28       Impact factor: 5.742

4.  Healthcare contact and treatment uptake following hepatitis C virus screening and counseling among rural Appalachian people who use drugs.

Authors:  Dustin B Stephens; April M Young; Jennifer R Havens
Journal:  Int J Drug Policy       Date:  2017-06-23

5.  The impact of lifetime drug use on hepatitis C treatment outcomes in insured members of an integrated health care plan.

Authors:  Marcia Russell; Mary Patricia Pauly; Charles Denton Moore; Constance Chia; Jennifer Mary Dorrell; Renee Junko Cunanan; Gayle Witt
Journal:  Drug Alcohol Depend       Date:  2013-10-12       Impact factor: 4.492

6.  Multiple variants in toll-like receptor 4 gene modulate risk of liver fibrosis in Caucasians with chronic hepatitis C infection.

Authors:  Yonghong Li; Monica Chang; Olivia Abar; Veronica Garcia; Charles Rowland; Joseph Catanese; David Ross; Samuel Broder; Mitchell Shiffman; Ramsey Cheung; Teresa Wright; Scott L Friedman; John Sninsky
Journal:  J Hepatol       Date:  2009-06-18       Impact factor: 25.083

7.  Age and ethnicity in cirrhosis.

Authors:  Krishna C Sajja; Desh P Mohan; Don C Rockey
Journal:  J Investig Med       Date:  2014-10       Impact factor: 2.895

Review 8.  Endocannabinoid signaling at the periphery: 50 years after THC.

Authors:  Mauro Maccarrone; Itai Bab; Tamás Bíró; Guy A Cabral; Sudhansu K Dey; Vincenzo Di Marzo; Justin C Konje; George Kunos; Raphael Mechoulam; Pal Pacher; Keith A Sharkey; Andreas Zimmer
Journal:  Trends Pharmacol Sci       Date:  2015-03-18       Impact factor: 14.819

9.  The association of non-O blood group and severity of liver fibrosis in patients with chronic hepatitis C infection.

Authors:  Ahmad Shavakhi; Mehri Hajalikhani; Mohammad Minakari; Alireza Norian; Rahil Riahi; Mina Azarnia; Lida Liaghat
Journal:  J Res Med Sci       Date:  2012-05       Impact factor: 1.852

Review 10.  Natural History of Hepatic and Extrahepatic Hepatitis C Virus Diseases and Impact of Interferon-Free HCV Therapy.

Authors:  Francesco Negro
Journal:  Cold Spring Harb Perspect Med       Date:  2020-04-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.